Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Completed · Phase 4

Conditions studied: Osteoarthritis, Controlled Hypertension

In brief

This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Key facts

Study ID

NCT00267176

Run by

Novartis Pharmaceuticals

People needed

1020

Starts

2005-11-01

Last updated by the study team

2017-02-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Osteoarthritis of the hand, hip, knee or spine
• High blood pressure (<140/ 90 mmHg) which is controlled by antihypertensive medication(s).

You may not qualify if…

• Evidence or history of any cardiac and cerebral thrombotic/ ischemic diseases and/ or events
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Southern Illinois Clinical Research — O'Fallon, Illinois, United States
• Novartis — Nuremberg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.